US equities |
NVDA $238.77 ▲+2.06% SPCX $168.12 ▲+5.76% MU $1,062.09 ▼-1.19% TSLA $380.25 ▲+2.61% MSFT $525.98 ▲+1.63% SNDK $1,701.62 ▼-1.07% INTC $116.97 ▼-1.98% META $742.74 ▲+2.01%
FinancialContent

Articles published by TerSera Therapeutics LLC

News headline image
ESTEVE to Acquire TerSera Therapeutics’ Infusion Specialty Therapies Business Unit, Expanding U.S. Presence
From TerSera Therapeutics LLC
Via Business Wire
News headline image
TerSera Therapeutics to Present Real-World Data on Intrathecal Ziconotide (PRIALT®) Prescription Patterns at ASPN 2025
From TerSera Therapeutics LLC
Via Business Wire
News headline image
TerSera® Receives National Recognition as a 2025 USA TODAY Top Workplace
From TerSera Therapeutics LLC
Via Business Wire
News headline image
TerSera® Presents New Real-World Evidence on Treatment Outcomes of Goserelin (ZOLADEX®) in Women with Breast Cancer at the 2024 San Antonio Breast Cancer Symposium
From TerSera Therapeutics LLC
Via Business Wire
News headline image
MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®
From TerSera Therapeutics LLC
Via Business Wire
Tickers MGNX
News headline image
TerSera® Presents Real-World Evidence on Treatment Patterns of Goserelin (ZOLADEX®) in Women with Breast Cancer at the 2024 American Society of Clinical Oncology (ASCO) Quality Care Symposium
From TerSera Therapeutics LLC
Via Business Wire
News headline image
Tersera Therapeutics LLC Announces That the 2024 Polyanalgesic Consensus Conference (PACC) Guidelines Issued Updated Guidance for Administering PRIALT
From TerSera Therapeutics LLC
Via Business Wire
News headline image
Goserelin Dosing Options Included in the National Comprehensive Cancer Network® (NCCN) Breast Cancer Guidelines
From TerSera Therapeutics LLC
Via Business Wire